• An innovation lab with 2 dedicated demo rooms for
  • Vectorio® and SeQure®;
  • SeQure® microcatheter pre-clinical data presentation;
  • 2 symposia in Oncology and Vascular Embolization.

Villepinte (France) - August 29, 2019 - 06:00pm (CEST) - Guerbet (FR0000032526 GBT), a global specialist of contrast agents and other solutions for medical imaging, will present its interventional imaging solutions offering at the CIRSE 2019 (Cardiovascular & Interventional Radiological Society of Europe) in Barcelona, Spain from September 7 to 11 2019 at booth #53 and in its Innovation Lab.

"CIRSE is the most prominent annual event organized for interventional radiology professionals and we will present our innovative solutions for interventional imaging along with Guerbet's flagship product Lipiodol® Ultra Fluid in our Innovation Lab with two demo rooms: 1 dedicated to Vectorio® and 1 dedicated to SeQure®, enabling interventional radiologists to discover and test them », said Guerbet Interventional Radiology Commercial VP Thomas Bonnefont. "We are continuing to develop our portfolio with the objective of helping healthcare professionals improve the quality of treatment in image-guided embolization procedures."


About Vectorio®:

Vectorio® is a Lipiodol® resistant mixing & injection system for conventional Trans-Arterial Chemo-Embolization (cTACE). It's a unique single use product resistant to Lipiodol® Ultra Fluid up to 24 hours. 4 patent families are concerning specific parts of Vectorio® system. Vectorio® obtained CE labelling in August 2017 and is registered in these followed countries: Austria, Belgium, Brazil, Croatia, France, Hong Kong, Hungary, Luxembourg, Mexico, New Zealand, Peru, Portugal, Czech Republic, South Korea,
Switzerland, Thailand, The Netherlands, Turkey, Vietnam.

Guerbet Innovation Lab - Vectorio®

Learn more on cTACE mixture standardization using Vectorio®
From September 7 to 10 - 09:00 - 12:00 and 1:00 - 6:00pm

By Philippe Havard (Global Head of Marketing), Amy Wei (Global Product Manager).

Press release

About SeQure® microcatheter:

The SeQure® microcatheter is an innovative reflux control microcatheter It consists of side slits which size has been specifically designed to allow the outflow of
contrast media, creating a fluid barrier around the microcatheter to reduce microspheres reflux and assist delivery to the target vessel. SeQure® obtained the CE
mark in April 2019. The SeQure® microcatheter received FDA clearance on January 26, 2018 and is commercialized on the US market. It is also registered in Australia, Brazil, Hong Kong, New Zealand, Thailand, Turkey.


Guerbet Innovation Lab - SeQure®

Discover SeQure® Control Reflux microcatheter - Flow dynamics based technology
From September 7 to 10 - 09:00 - 12:00am and 1:00 - 6:00pm

By Eleonora Manca (EMEA Applications Specialist) and Eam-Maly Nam (Global Product
Manager).

Reduced nontarget embolization and increased targeted delivery with SeQure®
microcatheter demonstrated in swine model

Pre-clinical study results at scientific session FP 1407 - Experimental studies in IR
On September 8 - 4:15 - 5:15 pm - Room 114

 By Prof. Geert Maleux, UZ Leuven, Belgium

Guerbet will also be organizing two symposia:
« Future perspectives in Lipiodol® use for liver diseases management » and « Vascular
Embolization: Improved delivery through better flow management » that will take place in
Room 117 respectively on Sunday, September 8 from 1 to 2 pm and Monday, September
9 from 11:30 am to 12:30 pm

Press release About Lipiodol® Ultra Fluid

Lipiodol® Ultra Fluid (ethyl esters of iodized fatty acids of poppyseed oil) was initially developed for diagnostic radiology in indications including liver lesion diagnosis, lymphography and hysterosalpingography, and then used in interventional radiology for conventional trans-arterial chemo-embolization (cTACE) procedures of multinodular hepatocellular carcinoma, where Lipiodol® Ultra Fluid is used as a procedure visualizer (contrast agent), a drug vehicle (drug carrier), and an embolic. The approved indications for Lipiodol® Ultra Fluid may vary according to countries. Please refer to local SmPC for further information.

Lipiodol® Ultra Fluid is not commercialized in Spain.

cTACE is an indication not authorized in Spain.

About Guerbet Guerbet is a pioneer in the contrast-agent field, with more than 90 years' experience, and is a leader in
medical imaging worldwide. It offers a comprehensive range of pharmaceutical products, medical devices and services for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. With 8% of revenue dedicated to R&D and its four centers in France, Israel and the United States, Guerbet is a substantial investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B - mid caps) and generated €790 million in revenue in 2018. For more information about Guerbet, please visit www.guerbet.com.

Attachments

  • Original document
  • Permalink

Disclaimer

Guerbet SA published this content on 28 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 October 2021 02:09:07 UTC.